(Q34663389)

3 August 2017

1 reference

title

Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma (English)

1 reference

3 August 2017

1 reference

1 reference

2

R N Brogden

1 reference

3 August 2017

R A Bartow

1

1 reference

3 August 2017

publication date

1 February 1998

1 reference

3 August 2017

1 reference

3 August 2017

volume

55

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

303-322

1 reference

Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

3 August 2017

cites work

1 reference

12 December 2020

Prolonged Protection against Methacholine-induced Bronchoconstriction by the Inhaled β2-Agonist Formoterol

1 reference

12 December 2020

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

12 December 2020

Protective effect and duration of action of formoterol aerosol on exercise-induced asthma

1 reference

12 December 2020

Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients.

1 reference

12 December 2020

Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma

1 reference

12 December 2020

Onset of action of eformoterol by dry powder inhaler: objective and subjective measures

1 reference

12 December 2020

Rapid onset of action of inhaled formoterol in asthmatic patients

1 reference

12 December 2020

Sustained improvement in asthma with long-term use of formoterol fumarate.

1 reference

12 December 2020

Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizerfi

1 reference

12 December 2020

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults

1 reference

12 December 2020

Why are long-acting beta-adrenoceptor agonists long-acting?

1 reference

12 December 2020

Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease

1 reference

12 December 2020

Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children

1 reference

12 December 2020

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

1 reference

12 December 2020

Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily

1 reference

12 December 2020

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

1 reference

12 December 2020

Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma

1 reference

12 December 2020

Long-Acting Inhaled Beta Agonists

1 reference

12 December 2020

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

12 December 2020

The effects of formoterol, a long-acting beta 2-adrenoceptor agonist, on mucociliary activity

1 reference

12 December 2020

Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo

1 reference

12 December 2020

A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol

1 reference

12 December 2020

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

The influence of a new beta agonist: formoterol on mucociliary function

1 reference

12 December 2020

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

12 December 2020

Guidelines for the management of asthma: a summary. British Thoracic Society and others

1 reference

12 December 2020

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

12 December 2020

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

12 December 2020

Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children

1 reference

12 December 2020

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

12 December 2020

[The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study]

1 reference

12 December 2020

Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists

1 reference

12 December 2020

Inhaled formoterol during one year in asthma: a comparison with salbutamol

1 reference

12 December 2020

Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist

1 reference

12 December 2020

Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study

1 reference

12 December 2020

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.

1 reference

12 December 2020

Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study

1 reference

12 December 2020

The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations

1 reference

12 December 2020

Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children

1 reference

12 December 2020

Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol

1 reference

12 December 2020

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

12 December 2020

Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council

1 reference

12 December 2020

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

12 December 2020

Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction--a placebo-controlled study

1 reference

12 December 2020

The use of beta 2-adrenoceptor agonists in the treatment of bronchial asthma

1 reference

12 December 2020

Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients

1 reference

12 December 2020

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

1 reference

12 December 2020

Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma

1 reference

12 December 2020

Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma

1 reference

12 December 2020

10.2165/00003495-199855020-00016

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1018055932

0 references

1 reference